PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millenium
- 31 January 2003
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 43 (1), 12-27
- https://doi.org/10.1016/s0302-2838(02)00505-5
Abstract
Prostate-specific antigen (PSA) progression following radical treatments of clinically localized prostate cancer is a common problem facing both the patient and the urologist. Not all patients with relapsing disease have an equal risk of death due to prostate cancer. After surgery, biochemical failure can be defined as persisting detectable levels of PSA after radical prostatectomy or a PSA rise after a period of normalization. On the other hand, definitions of PSA progression after radiation therapy vary and no clear consensus can be found. This review of the recent international literature updates the knowledge about the diagnostic procedures used in relapsing patients. Predictors of progression are precised leading to a better patient selection, based on currently available tables and nomograms. Indeed, identification of high risk patients may allow a more appropriate treatment decision. After radical treatment, the analysis of time to recurrence, PSA doubling time, PSA kinetics combined to modern imaging techniques such as 111In capromab penditide scan may allow a better identification of the recurrence site. Thus, an optimal treatment strategy may be envisaged such as local irradiation, salvage surgery, hormone therapy or combinations for which indications and results are provided. Alternative options such as cryotherapy still need further investigation. At last, the use of artificial neural networks will certainly enhance the selection of patients submitted to radical treatments as well as the selection of relapsing patients to allow a more appropriate adjuvant therapy.Keywords
This publication has 138 references indexed in Scilit:
- Artificial Neural Network Model To Predict Biochemical Failure After Radical ProstatectomyPublished by Mary Ann Liebert Inc ,2001
- PREDICTING RISK OF PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY WITH THE CENTER FOR PROSTATE DISEASE RESEARCH AND CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR DATABASESJournal of Urology, 2001
- PROSTATE SPECIFIC ANTIGEN BOUNCE AFTER RADIOACTIVE SEED IMPLANTATION FOLLOWED BY EXTERNAL BEAM RADIATION FOR PROSTATE CANCERJournal of Urology, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853European Urology, 1998
- Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomyThe Prostate, 1998
- Estrogens in the Treatment of Prostate CancerJournal of Urology, 1995
- The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancerCancer, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survivalJournal of Steroid Biochemistry, 1985